Telomerase Regulation: A Role for Epigenetics

被引:61
作者
Dogan, Fatma [1 ]
Forsyth, Nicholas R. [1 ,2 ]
机构
[1] Keele Univ, Fac Med & Hlth Sci, Sch Pharm & Bioengn, Guy Hilton Res Labs, Stoke On Trent ST4 7QB, Staffs, England
[2] Tongji Univ, Sch Med, Shanghai 200092, Peoples R China
关键词
telomerase; TERT; promoter; epigenetics; methylation; cancer; HISTONE DEACETYLASE INHIBITOR; TERT PROMOTER MUTATIONS; REVERSE-TRANSCRIPTASE GENE; CATALYTIC SUBUNIT HTERT; TUMOR-SUPPRESSOR GENES; LONG NONCODING RNA; DNA METHYLATION; MESSENGER-RNA; ACTIVE CHROMATIN; DOWN-REGULATION;
D O I
10.3390/cancers13061213
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Maintenance of telomeres is a fundamental step in human carcinogenesis and is primarily regulated by telomerase and the human telomerase reverse transcriptase gene (TERT). Improved understanding of the transcriptional control of this gene may provide potential therapeutic targets. Epigenetic modifications are a prominent mechanism to control telomerase activity and regulation of the TERT gene. TERT-targeting miRNAs have been widely studied and their function explained through pre-clinical in vivo model-based validation studies. Further, histone deacetylase inhibitors are now in pre and early clinical trials with significant clinical success. Importantly, TERT downregulation through epigenetic modifications including TERT promoter methylation, histone deacetylase inhibitors, and miRNA activity might contribute to clinical study design. This review provides an overview of the epigenetic mechanisms involved in the regulation of TERT expression and telomerase activity. Telomerase was first described by Greider and Blackburn in 1984, a discovery ultimately recognized by the Nobel Prize committee in 2009. The three decades following on from its discovery have been accompanied by an increased understanding of the fundamental mechanisms of telomerase activity, and its role in telomere biology. Telomerase has a clearly defined role in telomere length maintenance and an established influence on DNA replication, differentiation, survival, development, apoptosis, tumorigenesis, and a further role in therapeutic resistance in human stem and cancer cells including those of breast and cervical origin. TERT encodes the catalytic subunit and rate-limiting factor for telomerase enzyme activity. The mechanisms of activation or silencing of TERT remain open to debate across somatic, cancer, and stem cells. Promoter mutations upstream of TERT may promote dysregulated telomerase activation in tumour cells but additional factors including epigenetic, transcriptional and posttranscriptional modifications also have a role to play. Previous systematic analysis indicated methylation and mutation of the TERT promoter in 53% and 31%, respectively, of TERT expressing cancer cell lines supporting the concept of a key role for epigenetic alteration associated with TERT dysregulation and cellular transformation. Epigenetic regulators including DNA methylation, histone modification, and non-coding RNAs are now emerging as drivers in the regulation of telomeres and telomerase activity. Epigenetic regulation may be responsible for reversible silencing of TERT in several biological processes including development and differentiation, and increased TERT expression in cancers. Understanding the epigenetic mechanisms behind telomerase regulation holds important prospects for cancer treatment, diagnosis and prognosis. This review will focus on the role of epigenetics in telomerase regulation.
引用
收藏
页码:1 / 24
页数:25
相关论文
共 219 条
[1]   Long-Range Chromatin Interactions Drive Mutant TERT Promoter Activation [J].
Akincilar, Semih Can ;
Khattar, Ekta ;
Boon, Priscilla Li Shan ;
Unal, Bilal ;
Fullwood, Melissa Jane ;
Tergaonkar, Vinay .
CANCER DISCOVERY, 2016, 6 (11) :1276-1291
[2]  
Albanell J, 1996, CANCER RES, V56, P1503
[3]   DNA-DAMAGE IN HUMAN B-CELLS CAN INDUCE APOPTOSIS, PROCEEDING FROM G(1)/S WHEN P53 IS TRANSACTIVATION COMPETENT AND G(2)/M WHEN IT IS TRANSACTIVATION DEFECTIVE [J].
ALLDAY, MJ ;
INMAN, GJ ;
CRAWFORD, DH ;
FARRELL, PJ .
EMBO JOURNAL, 1995, 14 (20) :4994-5005
[4]  
[Anonymous], 2010, P AM THOR SOC INT 20, DOI DOI 10.1164/AJRCCM-CONFERENCE.2010.181.1_MEETINGABSTRACTS.A2297
[5]   Lack of telomerase gene expression in alternative lengthening of telomere cells is associated with chromatin remodeling of the hTR and hTERT gene promoters [J].
Atkinson, SP ;
Hoare, SF ;
Glasspool, RM ;
Keith, WN .
CANCER RESEARCH, 2005, 65 (17) :7585-7590
[6]   The structure and function of telomerase reverse transcriptase [J].
Autexier, Chantal ;
Lue, Neal F. .
ANNUAL REVIEW OF BIOCHEMISTRY, 2006, 75 :493-517
[7]  
Avilion AA, 1996, CANCER RES, V56, P645
[8]   Characterization of human telomerase reverse transcriptase promoter methylation and transcription factor binding in differentiated thyroid cancer cell lines [J].
Avin, Brittany A. ;
Wang, Yongchun ;
Gilpatrick, Timothy ;
Workman, Rachael E. ;
Lee, Isac ;
Timp, Winston ;
Umbricht, Christopher B. ;
Zeiger, Martha A. .
GENES CHROMOSOMES & CANCER, 2019, 58 (08) :530-540
[9]   Frequent recombination in telomeric DNA may extend the proliferative life of telomerase-negative cells [J].
Bailey, SM ;
Brenneman, MA ;
Goodwin, EH .
NUCLEIC ACIDS RESEARCH, 2004, 32 (12) :3743-3751
[10]   Regulation of chromatin by histone modifications [J].
Bannister, Andrew J. ;
Kouzarides, Tony .
CELL RESEARCH, 2011, 21 (03) :381-395